lat1

LAT1-IN-1 (BCH) is a selective and competitive inhibitor of L-type amino acid transporter protein 1 (LAT1). LAT1-IN-1 has antitumor activity, inducing apoptosis in tumor cells and inhibiting cell proliferation.

JPH203 (KYT-0353) is a potent and specific inhibitor of L-type amino acid transporter protein 1 (LAT-1). JPH203 inhibits cellular uptake of leucine, inhibits cell proliferation, induces apoptosis, and possesses anti-inflammatory and anti-tumor activities.

MALAT1-IN-1 modulated Malat1 downstream genes in a dose-dependent manner without affecting the expression of nuclear enriched abundant transcript 1 (Neat1). MALAT1-IN-1 is an effective and specific Malat1 inhibitor.

JPH203 dihydrochloride (KYT-0353 dihydrochloride) is a tyrosine analog, acts as a selective inhibitor of L-type amino acid transporter 1 (LAT1), and is used in cancer research.

GPNA hydrochloride is specific glutamine (Gln) transporter ASCT2(SLC1A5) inhibitor. GPNA reversibly induces apoptosis in A549 cells. GPNA hydrochloride is a well-known substrate of the enzyme γ-glutamyltransferase (GGT). GPNA hydrochloride also inhibits

KMH-233 is a potent selective LAT1 inhibitor 1 that inhibits the uptake of LAT1 substrate, L-leucine, and cell growth. Even at low concentrations (25 μM), it significantly enhanced the efficacy of betastatin and cisplatin.

QBS10072S is a bifunctional chemotherapeutic agent that exerts its effects by combining a cytotoxin with a selective LAT1 transporter substrate. It demonstrates cytotoxicity in MDA-MB-231 cells and exhibits antitumor activity in mice. Additionally, QBS10072S possesses blood-brain barrier (BBB) permeability.

KHK-2898 represents a highly specialized humanized monoclonal antibody specifically engineered to target the CD98 heavy chain (CD98hc/SLC3A2) with exceptional binding affinity to the human and monkey LAT1/CD98hc complex. It effectively facilitates the measurable blockade of amino acid transport and the induction of potent antibody-dependent cellular cytotoxicity (ADCC) across various preclinical experimental models to evaluate the disruption of tumor nutrient uptake and metabolic homeostasis during strictly monitored laboratory observation periods and functional cell viability assays.

L-Citrulline (Standard) is available for quantitative analysis.) L-Citrulline is a non-essential amino acid involved in the nitric oxide cycle and the urea cycle, promotes vasodilatation, has antioxidant and anti-inflammatory properties, is orally available, and crosses the blood-brain barrier through LAT1. It is an agonist of eNOS (endothelial nitric oxide synthase), iNOS (inducible nitric oxide synthase), and mTORC1 (rapamycin targeting protein complex 1), and an inhibitor of SREBP-1 (sterol regulatory element binding protein 1).

(R)-KMH-233 is an isomer of KMH-233, which can serve as a reference compound in experiments. KMH-233 functions as a potent, reversible, and selective inhibitor of L-type amino acid transporter 1 (LAT1), effectively hindering the uptake of LAT1 substrate, l-leucine (IC50=18 μM), and also inhibiting cell growth. Even at a low concentration of 25 μM, KMH-233 significantly enhances the efficacy of Bestatin and cisplatin.